Comprehensive serum proteomics analysis after CD19-targeted CAR-T therapy indicates that FMS-like tyrosine kinase 3 (FLT3) and mast cell immunoglobulin-like receptor 1 (MILR1) are pre-infusion predictive biomarkers for severe CRS (124). Here, MILR1 is linked to congenital rubella syndrome.